Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$9.4 - $18.59 $1.41 Million - $2.79 Million
-150,000 Reduced 75.0%
50,000 $897,000
Q2 2022

Aug 16, 2022

SELL
$9.12 - $18.9 $1.55 Million - $3.21 Million
-170,000 Reduced 45.95%
200,000 $1.92 Million
Q1 2022

May 11, 2022

BUY
$12.15 - $16.83 $1.76 Million - $2.44 Million
145,000 Added 64.44%
370,000 $6.23 Million
Q4 2021

Feb 14, 2022

SELL
$13.83 - $18.78 $345,750 - $469,500
-25,000 Reduced 10.0%
225,000 $3.76 Million
Q3 2021

Nov 12, 2021

SELL
$7.07 - $17.5 $1.06 Million - $2.63 Million
-150,000 Reduced 37.5%
250,000 $4.06 Million
Q2 2021

Aug 13, 2021

SELL
$5.69 - $7.17 $995,750 - $1.25 Million
-175,000 Reduced 30.43%
400,000 $2.52 Million
Q1 2021

May 12, 2021

SELL
$5.08 - $6.89 $1.4 Million - $1.89 Million
-275,000 Reduced 32.35%
575,000 $3.55 Million
Q4 2020

Feb 10, 2021

SELL
$5.65 - $7.66 $282,500 - $383,000
-50,000 Reduced 5.56%
850,000 $5.81 Million
Q3 2020

Nov 12, 2020

SELL
$4.01 - $6.29 $401,000 - $629,000
-100,000 Reduced 10.0%
900,000 $5.08 Million
Q2 2020

Aug 11, 2020

SELL
$3.06 - $6.6 $765,000 - $1.65 Million
-250,000 Reduced 20.0%
1,000,000 $5.1 Million
Q1 2020

May 14, 2020

SELL
$2.83 - $8.44 $3.96 Million - $11.8 Million
-1,400,000 Reduced 52.83%
1,250,000 $4.3 Million
Q4 2019

Feb 11, 2020

SELL
$0.93 - $8.58 $325,500 - $3 Million
-350,000 Reduced 11.67%
2,650,000 $21.6 Million
Q2 2019

Aug 12, 2019

BUY
$1.21 - $1.48 $3.63 Million - $4.44 Million
3,000,000 New
3,000,000 $3.72 Million

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Tamarack Advisers, LP Portfolio

Follow Tamarack Advisers, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tamarack Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Tamarack Advisers, LP with notifications on news.